Floatz logo

Anti-Cd19 And Anti-Cd20 Bicistronic Car T- Cells

Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)Cell therapyPhase 1Active
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

143 Active assets in the Chronic Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
CHLORAMBUCIL
Ascentage Pharma Group Inc.
Phase 4BBB
Venetoclax
City of Hope Medical Center
Phase 4BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 4BB
Zofran
Dizal Pharmaceuticals
Phase 4BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

Anti-Cd19 And Anti-Cd20 Bicistronic Car T- Cells is also rated in:

B-Cell Chronic Lymphocytic LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →
Lymphoma, B-CellDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →